- Marketwired•15 days ago
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
Prima BioMed Ltd announces that the second cohort comprising six patients has now been fully recruited for its TACTI-mel clinical trial being conducted in Australia. Patients with unresectable or metastatic ...
- Investopedia•last month
Prima is running trials to treat breast cancer and skin cancer using combinations of its drug IMP321.
PRR.AX : Summary for PRIMA FPO - Yahoo Finance
Prima Biomed Ltd. (PRR.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||0.03 - 0.03|
|52 Week Range||0.03 - 0.05|
|PE Ratio (TTM)||-7.75|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|